Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$161.52+0.73 (+0.45%)
Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –
Novartis Core Net Income Growth (% cc) by Quarter
Core Net Income Growth (% cc) (%)
Novartis Core Net Income Growth (% cc): 6.0% in Q3 2026, unchanged from a year earlier.
Latest, Q3 2026
6.0%
Period ended Sep 30, 2026
Change on a year earlier
0.0 pts
6.0% in Q3 2025
History
7 quarters
Since Q1 2025
Sources
7
Documents cited below
Where the Q3 2026 figure comes from
“|| Core net income | 4 655 | 4 330 | 8 | 6 | 13 027 | 13 522 | -4 | -5”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Core Net Income Growth (% cc) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 6.0% | 0.0 pts | Novartis Form 6-K (0001114448-26-000014) ↗ |
| Q2 2026 | Jun 30, 2026 | -4.0% | -23.0 pts | Novartis Form 6-K (0001114448-26-000012) ↗ |
| Q1 2026 | Mar 31, 2026 | -17.0% | -43.0 pts | Novartis Form 6-K (0001114448-26-000010) ↗ |
| Q4 2025 | Dec 31, 2025 | -2.0% | – | Novartis Form 6-K (0001114448-26-000007) ↗ |
| Q3 2025 | Sep 30, 2025 | 6.0% | – | Novartis Form 6-K (0001114448-25-000003) ↗ |
| Q2 2025 | Jun 30, 2025 | 19.0% | – | Novartis Form 6-K (0001370368-25-000012) ↗ |
| Q1 2025 | Mar 31, 2025 | 26.0% | – | Novartis Form 6-K (0001370368-25-000010) ↗ |
Cite this data
StockData. (2026). Novartis Core Net Income Growth (% cc) (%), quarterly Q1 2025–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/core-net-income-yoy-cc-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.